Hologic stock (US4364401012): AI imaging study and Nasdaq listing in focus

Hologic is in focus after a company newsroom item on AI-enabled 3DQuorum imaging on 06/03/2026, while the Nasdaq-listed women’s health group remains backed by a consensus price target from MarketBeat.

Hologic drew attention on 06/03/2026 after its newsroom highlighted new published data on the company’s AI-linked 3DQuorum imaging technology, which is designed to help streamline mammography reviews, according to Hologic’s newsroom. The stock traded at USD 62.10 on 06/03/2026 on Nasdaq, according to MarketBeat as of 06/03/2026.

For investors following the United States-listed name, the latest public stock data on Nasdaq shows Hologic under ticker HOLX, with the company based in Marlborough, Massachusetts, and focused on women’s health and medical technology. MarketBeat’s snapshot also showed an average price target of USD 79.09 across analysts it tracks, implying a consensus reference point rather than a company-provided forecast, according to MarketBeat as of 06/03/2026.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Hologic
• Sector/industry: Medical technology / health care equipment
• Headquarters/country: Marlborough, United States
• Core markets: United States, Europe, and other international markets
• Key revenue drivers: Diagnostic products, imaging systems, and surgical solutions for women’s health
• Home exchange/listing venue: Nasdaq (HOLX)
• Trading currency: USD

Hologic: core business model

Hologic develops diagnostic, imaging, and surgical systems for women’s health, with its product portfolio spanning breast health, skeletal health, gynecological conditions, and molecular diagnostics.

Hologic in peer comparison

Compared with other large medical technology names, Hologic sits in a narrower specialty niche: its women’s-health focus differentiates it from broader device makers such as Danaher and Becton, Dickinson, while keeping the company exposed to recurring diagnostic and procedure-driven demand.

MarketBeat classifies Hologic in the medical instruments sub-industry, alongside a mix of equipment and diagnostics peers, which helps frame valuation and growth expectations relative to more diversified medtech groups.

Conclusion

Hologic's latest newsroom update keeps the Nasdaq-listed stock in view as investors look for evidence that AI-related imaging tools can support clinical adoption and product differentiation. The peer comparison context also shows why the market continues to judge Hologic against a broad medtech set rather than only women's-health specialists.

The company's image remains tied to diagnostics and procedure-led revenue streams, so any sustained momentum in new imaging workflows may matter more than a single press release.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.